Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer
We evaluated the therapeutic efficacy and toxicity of a tandem high-dose therapy with peripheral blood stem cell (PBSC) support in 40 patients with high-risk, primary breast cancer (stage II-III) and involvement of ten or more positive axillary lymph nodes. Their median age was 44 years (range 23-56...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1997
|
| In: |
European journal of cancer
Year: 1997, Jahrgang: 33, Heft: 3, Pages: 372-378 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/S0959-8049(97)89008-9 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S0959-8049(97)89008-9 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804997890089 
|
| Verfasserangaben: | R. Haas, H. Schmid, U. Hahn, S. Hohaus, H. Goldschmidt, S. Murea, M. Kaufmann, M. Wannenmacher, D. Wallwiener, G. Bastert, W. Hunstein |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1883748097 | ||
| 003 | DE-627 | ||
| 005 | 20240703154549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240319s1997 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0959-8049(97)89008-9 |2 doi | |
| 035 | |a (DE-627)1883748097 | ||
| 035 | |a (DE-599)KXP1883748097 | ||
| 035 | |a (OCoLC)1443657331 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Haas, Rainer |d 1955- |e VerfasserIn |0 (DE-588)173773524 |0 (DE-627)698678141 |0 (DE-576)134613805 |4 aut | |
| 245 | 1 | 0 | |a Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer |c R. Haas, H. Schmid, U. Hahn, S. Hohaus, H. Goldschmidt, S. Murea, M. Kaufmann, M. Wannenmacher, D. Wallwiener, G. Bastert, W. Hunstein |
| 264 | 1 | |c 1997 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Elektronische Reproduktion der Druck-Ausgabe 22. Juli 2002 | ||
| 500 | |a Gesehen am 19.03.2024 | ||
| 520 | |a We evaluated the therapeutic efficacy and toxicity of a tandem high-dose therapy with peripheral blood stem cell (PBSC) support in 40 patients with high-risk, primary breast cancer (stage II-III) and involvement of ten or more positive axillary lymph nodes. Their median age was 44 years (range 23-56). Two cycles of cytotoxic chemotherapy with ifosfamide (10000 mg/m2) and epirubicin (100 mg/m2) were administered. Granulocyte colony-stimulating factor (G-CSF) was given to hasten neutrophil reconstitution and to mobilise PBSC during marrow recovery. Leukaphereses were performed following the first and/or second cycle. Tandem high-dose therapy consisted of two cycles with ifosfamide (15 or 12 g/m2) and epirubicin (150 mg/m2), while carboplatin (900 mg/m2) was added for the last 24 patients included. Using an immunocytochemical method, two of 11 patients had cytokeratin-positive tumour cells in three leukapheresis products that were collected following the first G-CSF-supported cycle with ifosfamide and epirubicin, whereas only two harvests obtained following the second cycle in 26 patients contained cytokeratin-positive tumour cells. The number of CD34+ cells/kg re-infused following both high-dose cycles was similar (4.20 ± 0.29 × 106, first cycle and 5.25 ± 0.63 × 106, second cycle), and no notable difference was noted in the speed of haematological reconstitution. An absolute neutrophil count (ANC) of 0.5 × 109/l was reached after a median time of 13 days, while an unsupported platelet count of 20.0 × 109/1 was achieved after a median time of 8 (first cycle) and 9 (second cycle) days post-transplantation. Patients autografted with more than 7.5 × 106 CD34+ cells/kg had platelet counts above 20 × 109/1 within less than 10 days. 6 patients relapsed between 7 and 11 months (median 8 months) post-transplantation. 37 patients are alive and in remission with a median follow-up time of 11 months (range 1-38). This translates into a probability of disease-free survival (DFS) of 77% (95% CI 32-95%) at 38 months. The probability of overall survival is 85%, since 3 patients with local relapse achieved a second complete remission following surgery and involved-field radiotherapy. In conclusion, a sequential high-dose therapy including ifosfamide, epirubicin, carboplatin and PBSC support is well tolerated and effective in patients with high-risk primary breast cancer. Involved-field irradiation should be performed post-transplantation to reduce the risk of local relapse. | ||
| 650 | 4 | |a peripheral blood stem cell support | |
| 650 | 4 | |a primary breast cancer | |
| 650 | 4 | |a tandem high-dose therapy | |
| 700 | 1 | |a Schmid, Hans |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hahn, Uwe |d 1960- |e VerfasserIn |0 (DE-588)125272182X |0 (DE-627)179419102X |4 aut | |
| 700 | 1 | |a Hohaus, Stefan |e VerfasserIn |0 (DE-588)1084809745 |0 (DE-627)848733983 |0 (DE-576)168163020 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Murea, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaufmann, Manfred |d 1946- |e VerfasserIn |0 (DE-588)124330193 |0 (DE-627)08579046X |0 (DE-576)294122710 |4 aut | |
| 700 | 1 | |a Wannenmacher, Michael |d 1938-2015 |e VerfasserIn |0 (DE-588)115523588 |0 (DE-627)077305582 |0 (DE-576)289929717 |4 aut | |
| 700 | 1 | |a Wallwiener, Diethelm |d 1954- |e VerfasserIn |0 (DE-588)121922413 |0 (DE-627)081622147 |0 (DE-576)16771726X |4 aut | |
| 700 | 1 | |a Bastert, Gunther |d 1939- |e VerfasserIn |0 (DE-588)171967526 |0 (DE-627)696863006 |0 (DE-576)164650563 |4 aut | |
| 700 | 1 | |a Hunstein, Werner |d 1928-2012 |e VerfasserIn |0 (DE-588)1012782662 |0 (DE-627)699775833 |0 (DE-576)345935667 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 33(1997), 3, Seite 372-378 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer |
| 773 | 1 | 8 | |g volume:33 |g year:1997 |g number:3 |g pages:372-378 |g extent:7 |a Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S0959-8049(97)89008-9 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804997890089 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240319 | ||
| 994 | |a 1997 | ||
| 998 | |g 1012782662 |a Hunstein, Werner |m 1012782662:Hunstein, Werner |d 910000 |d 910100 |e 910000PH1012782662 |e 910100PH1012782662 |k 0/910000/ |k 1/910000/910100/ |p 11 |y j | ||
| 998 | |g 171967526 |a Bastert, Gunther |m 171967526:Bastert, Gunther |d 910000 |d 910400 |e 910000PB171967526 |e 910400PB171967526 |k 0/910000/ |k 1/910000/910400/ |p 10 | ||
| 998 | |g 121922413 |a Wallwiener, Diethelm |m 121922413:Wallwiener, Diethelm |d 910000 |d 910400 |e 910000PW121922413 |e 910400PW121922413 |k 0/910000/ |k 1/910000/910400/ |p 9 | ||
| 998 | |g 115523588 |a Wannenmacher, Michael |m 115523588:Wannenmacher, Michael |d 910000 |d 911400 |e 910000PW115523588 |e 911400PW115523588 |k 0/910000/ |k 1/910000/911400/ |p 8 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1084809745 |a Hohaus, Stefan |m 1084809745:Hohaus, Stefan |d 910000 |d 910100 |e 910000PH1084809745 |e 910100PH1084809745 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 125272182X |a Hahn, Uwe |m 125272182X:Hahn, Uwe |d 910000 |d 910100 |e 910000PH125272182X |e 910100PH125272182X |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 173773524 |a Haas, Rainer |m 173773524:Haas, Rainer |d 910000 |d 910100 |e 910000PH173773524 |e 910100PH173773524 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1883748097 |e 4501546530 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"family":"Haas","display":"Haas, Rainer","given":"Rainer","role":"aut"},{"display":"Schmid, Hans","family":"Schmid","given":"Hans","role":"aut"},{"display":"Hahn, Uwe","family":"Hahn","given":"Uwe","role":"aut"},{"role":"aut","given":"Stefan","family":"Hohaus","display":"Hohaus, Stefan"},{"role":"aut","given":"Hartmut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"},{"given":"S.","role":"aut","family":"Murea","display":"Murea, S."},{"display":"Kaufmann, Manfred","family":"Kaufmann","given":"Manfred","role":"aut"},{"given":"Michael","role":"aut","display":"Wannenmacher, Michael","family":"Wannenmacher"},{"role":"aut","given":"Diethelm","display":"Wallwiener, Diethelm","family":"Wallwiener"},{"display":"Bastert, Gunther","family":"Bastert","given":"Gunther","role":"aut"},{"display":"Hunstein, Werner","family":"Hunstein","role":"aut","given":"Werner"}],"name":{"displayForm":["R. Haas, H. Schmid, U. Hahn, S. Hohaus, H. Goldschmidt, S. Murea, M. Kaufmann, M. Wannenmacher, D. Wallwiener, G. Bastert, W. Hunstein"]},"physDesc":[{"extent":"7 S."}],"recId":"1883748097","relHost":[{"recId":"266883400","id":{"zdb":["1468190-0"],"issn":["1879-0852"],"eki":["266883400"]},"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"pubHistory":["28.1992 -"],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"origin":[{"dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisher":"Elsevier ; Pergamon Press","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}],"disp":"Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancerEuropean journal of cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"titleAlt":[{"title":"EJC online"}],"part":{"pages":"372-378","year":"1997","issue":"3","text":"33(1997), 3, Seite 372-378","extent":"7","volume":"33"},"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"display":"European Association for Cancer Research","role":"isb"},{"display":"European School of Oncology","role":"isb"}]}],"id":{"doi":["10.1016/S0959-8049(97)89008-9"],"eki":["1883748097"]},"note":["Elektronische Reproduktion der Druck-Ausgabe 22. Juli 2002","Gesehen am 19.03.2024"],"origin":[{"dateIssuedDisp":"1997","dateIssuedKey":"1997"}],"title":[{"title_sort":"Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer","title":"Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a HAASRAINERTANDEMHIGH1997 | ||